CN112707816B - Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof - Google Patents

Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof Download PDF

Info

Publication number
CN112707816B
CN112707816B CN201911022214.8A CN201911022214A CN112707816B CN 112707816 B CN112707816 B CN 112707816B CN 201911022214 A CN201911022214 A CN 201911022214A CN 112707816 B CN112707816 B CN 112707816B
Authority
CN
China
Prior art keywords
vanadate
acid
insulin
alkoxy derivative
anhydride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911022214.8A
Other languages
Chinese (zh)
Other versions
CN112707816A (en
Inventor
陈坤
殷盼超
刘媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China University of Technology SCUT
Original Assignee
South China University of Technology SCUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China University of Technology SCUT filed Critical South China University of Technology SCUT
Priority to CN201911022214.8A priority Critical patent/CN112707816B/en
Publication of CN112707816A publication Critical patent/CN112707816A/en
Application granted granted Critical
Publication of CN112707816B publication Critical patent/CN112707816B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a poly-vanadate alkoxy derivative with insulin sensitizing activity, and a preparation method and application thereof. According to the method, acid anhydride or fatty acid or benzoic acid and vanadate or vanadate are subjected to one-step esterification reaction to prepare the poly-vanadate alkoxy derivative. The polyvanadate alkoxy derivative can quickly reduce the blood sugar of a diabetic mouse, and the combination use of the polyvanadate alkoxy derivative and insulin can better control the blood sugar compared with the single use of the insulin, so that the glucose responsiveness and the lasting activity of the insulin are promoted, the administration frequency of the insulin can be reduced, the experience that animals suffer from hyperglycemia and hypoglycemia states at the same time is reduced, and the fidelity of the blood sugar control in the insulin treatment is further improved.

Description

Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof
Technical Field
The invention belongs to the field of animal medicine, and particularly relates to a poly-vanadate alkoxy derivative with insulin sensitizing activity, and a preparation method and application thereof.
Background
In recent years, the number of dogs and cats suffering from diabetes in pet hospitals is gradually increased. Canine and feline diabetes belongs to endocrine diseases, is clinically characterized by hyperglycemia, diabetes, polyuria, polydipsia and bulimia, and causes cardiovascular diseases such as cataract, blindness, hair loss, heart failure and the like of pets at the end stage. Insulin resistance plays a crucial role in the pathophysiology of diabetes and vascular disease in dogs and cats. Exogenous insulin is used clinically to treat diabetic dogs and cats for the purpose of controlling blood glucose. However, it is difficult for diabetic dogs and cats to strictly follow the insulin treatment regimen, and serious complications may cause diabetic dogs and cats to experience a hyperglycemic or hypoglycemic state. Long-term instability of blood glucose levels can lead to cardiovascular disease in diabetic dogs, cats and can lead to higher mortality rates. Therefore, there is a need to find effective insulin sensitizers to reduce vascular and metabolic diseases in diabetic dogs and cats.
Vanadium compounds are well known for their anti-diabetic effects in glucose and lipid metabolism. Due to the similarity in size and charge of phosphorus and vanadium, vanadium is an essential element in most organisms and accumulates in the participation of some oxygen-containing organisms in biological processes. Over the last decade, hundreds of vanadium compounds, especially organic derivatives, have been used to treat diabetes. Activation of insulin receptors by vanadate affects the balance of insulin response to glucose. Vanadium complexes, mainly VV and VIV compounds with organic ligands such as maltol (BMOV) and ethyl maltol (BEOV), have been extensively studied to exploit their effects in the treatment of diabetes, given the potential for vanadium complexes to reduce the side effects of inorganic metal drug demetallization and degradation in humans. BMOV and BEOV are currently the only VCs entering clinical trials due to extremely low oral bioavailability (1% on average) and potential long-term toxicity, but were prevented in phase II clinical trials.
Disclosure of Invention
In order to solve the defects and shortcomings of the prior art, the invention aims to provide a poly-vanadate alkoxy derivative with insulin sensitizing activity. The polyvanadate alkoxy derivative is mainly realized by forming the polyvanadate alkoxy derivative through covalent modification of POVs (polyvanadate) and fatty acids such as acetic acid, caproic acid, capric acid, myristic acid, stearic acid and benzoic acid, and can promote the response of diabetic dogs and cats to glucose and enable insulin of the diabetic dogs and cats to have lasting activity.
The invention also aims to provide a preparation method of the polyvanadate alkoxy derivative with insulin sensitizing activity. The poly-vanadate/poly-vanadate and the anhydride/acid/benzoic acid are obtained by esterification reaction under the action of an esterification reaction catalyst, the preparation method is simple, and fatty acids with different chain lengths can be connected to hexavanadate through one-step esterification reaction.
The invention also aims to provide application of the polyvanadate alkoxy derivative with insulin sensitizing activity in the biomedical field. Through regulating and controlling the chain length of fatty acid in the poly-vanadate alkoxy derivative, the sensitization activity of the poly-vanadate alkoxy derivative on insulin is regulated, so that the blood sugar level of an organism is regulated, the blood sugar level of a diabetic dog or a diabetic cat is stabilized, and complications caused by unstable blood sugar are reduced.
The purpose of the invention is realized by the following technical scheme:
a poly vanadate alkoxy derivative with insulin sensitizing activity has a molecular formula of A2[V6O13{(OCH2)3CCH2OCOR}2]3、A2[V10O18{(OCH2)3CCH2OCOR}2]3、B2[V6O13{(OCH2)3CCH2OCOR}2]Or B2[V10O18{(OCH2)3CCH2OCOR}2]Wherein A is Al or Fe, B is tetrabutylammonium, Na or H, R is phenyl or alkyl containing 1-17 carbon atoms, A or B and [ V ]6O13{(OCH2)3CCH2OCOR}2]By ionic bond, A or B with [ V ]10O18{(OCH2)3CCH2OCOR}2]Is connected with an ionic bond.
The R is preferably CH3、(CH2)4CH3、(CH2)8CH3、(CH2)12CH3、(CH2)16CH3And C6H5One kind of (1).
The poly vanadate alkoxy derivative with insulin sensitizing activity is an ionic compound, wherein the cation of the poly vanadate alkoxy derivative is a cation corresponding to A or B, and the anion of the poly vanadate alkoxy derivative is [ V ]6O13{(OCH2)3CCH2OCOR}2]2-Or [ V ]10O18{(OCH2)3CCH2OCOR}2]2-。
The preparation method of the poly-vanadate alkoxy derivative with the insulin sensitizing activity comprises the following steps:
mixing vanadate or vanadate with anhydride or fatty acid or benzoic acid uniformly, adding an esterification reaction catalyst and an organic solvent, reacting at 60-100 ℃ for 36-60 hours, cooling, purifying, and then carrying out cation exchange to obtain a poly-vanadate alkoxy derivative with insulin sensitizing activity;
the vanadic acid is hexa-vanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) Or decavanadic acid (Bu)4N)2[V10O18{(OCH2)3CCH2OH}2]The vanadate is hexavanadate or decavanadate;
the molar ratio of the vanadate or vanadate to the anhydride or fatty acid or benzoic acid is 1: 2 to 3.
The concentration of the acid anhydride or the fatty acid or the benzoic acid in the organic solvent is 0.05-1 mol/L, and preferably 0.1 mol/L.
The organic solvent is at least one of triethylamine, acetonitrile, N' -Dimethylformamide (DMF) and dimethyl sulfoxide (DMSO); preferably triethylamine and acetonitrile in a ratio of 1 mmol: the obtained mixed solvent was mixed in a proportion of 10 mL.
The esterification catalyst is preferably 4-Dimethylaminopyridine (DMAP) or N, N' -Dicyclohexylcarbodiimide (DCC).
The molar ratio of the esterification reaction catalyst to acid anhydride or fatty acid or benzoic acid is (0.01-2): 1; preferably 0.4-1.4: 1.
the acid anhydride is preferably at least one of acetic anhydride, hexanoic anhydride, decanoic anhydride, myristic anhydride, creatinine, stearic anhydride, and benzoic anhydride.
The fatty acid is preferably a fatty acid having 1 to 18 carbon atoms, and more preferably at least one of acetic acid, caproic acid, capric acid, myristic acid, and stearic acid.
The purification method is preferably: and pouring the product mixed solution obtained after cooling into deionized water, and collecting the precipitate.
The cation exchange is carried out by using a cation exchange resin.
The vanadate is preferably at least one of bismuth vanadate, sodium vanadate, copper vanadate, ammonium vanadate, iron vanadate, calcium vanadate, zinc vanadate and silver vanadate.
The poly-vanadate alkoxy derivative with the insulin sensitizing activity is applied to the field of biomedicine.
Preferably in the preparation of animal medicine, more preferably in the preparation of medicine for regulating insulin sensitizing activity.
The technical principle of the invention is as follows: the method for obtaining the long-acting amphiphilic insulin sensitizer POV derivative by covalently modifying hexavanadate/hexavanadate or decavanadate/decavanadate combined with an aliphatic structure domain is adopted by the method for obtaining the long-acting vanadium compound. Vanadium itself has an insulin sensitizing effect. The POV derivative can be reversibly combined with plasma protein to different degrees after entering circulation, and as the volume of the drug molecule is increased after the POV derivative is combined with protein macromolecules, the combined POV derivative is not easy to penetrate out of the blood vessel wall, limits the transmembrane transport of the POV derivative, is not easy to metabolize or excrete, prolongs the action time of the POV derivative in the body, and thus, the long-acting insulin sensitizing effect is generated.
Compared with the prior art, the invention has the following advantages and beneficial effects:
(1) the synthesis process of the poly-vanadate alkoxy derivative with insulin sensitizing activity is simple and easy to implement, alkyl or phenyl with different chain lengths can be modified on vanadate through a simple one-step esterification reaction, the process quality of a product is easy to control, and the industrial production is facilitated.
(2) The poly vanadate alkoxy derivative with the insulin sensitizing activity is mainly realized by forming the poly vanadate alkoxy derivative through covalent modification of POVs and acid anhydride or fatty acid or benzoic acid, and the effective sensitizer can increase the sensitivity of an organism to insulin so as to adjust the blood sugar level of the organism, stabilize the blood sugar level of diabetic animals, reduce complications caused by unstable blood sugar and reduce vascular diseases and metabolic diseases.
(3) According to the invention, fatty acid or acid anhydride containing different carbon chain numbers is adopted to carry out covalent modification on polyvanadate, so that the persistent insulin sensitizing activity is provided for the polyvanadate alkoxy derivative, and the insulin sensitizing effect is shown in a diabetes model mouse. In addition, in healthy mice, the POV derivative has a low hypoglycemic index, and can better avoid unnecessary hypoglycemia symptoms.
(4) The poly-vanadate alkoxy derivative with the insulin sensitizing activity has the advantages of easily available raw materials and simple preparation method; compared with the single use of insulin, the combined use of the poly-vanadate alkoxy derivative and the insulin can better control blood sugar, and simultaneously, the insulin sensitizing activity of the vanadate alkoxy derivative can be regulated and controlled through the length of an alkyl chain, so that a method for maintaining the blood sugar level in an application range during the treatment of the insulin is provided.
(5) The polyvanadate alkoxy derivative with insulin sensitization activity can effectively control the blood sugar level of a diabetic mouse for a long time, so that the blood sugar is stabilized in a certain range and does not fluctuate too much, and the mouse is prevented from being influenced by the state of overhigh blood sugar or overhigh blood sugar.
Drawings
FIG. 1 is a synthesis scheme of poly-vanadate alkoxy derivatives with insulin sensitizing activity prepared by reacting hexavanadate with different acid anhydrides.
FIG. 2 is a graph showing the effect of V6-C10 (in an amount of 5mg/kg) prepared in example 3 on the blood glucose level of STZ-induced diabetic mice.
FIG. 3 is a graph showing the effect of V6-C14 (in an amount of 5mg/kg) prepared in example 4 on the blood glucose level of STZ-induced diabetic mice.
FIG. 4 is a graph showing the effect of V6-C18 (in an amount of 5mg/kg) prepared in example 5 on the blood glucose level of STZ-induced diabetic mice.
FIG. 5 is a graph showing the effect of V6-phen (in an amount of 5mg/kg) prepared in example 6 on blood glucose in STZ-induced diabetic mice.
FIG. 6 is a graph showing the change in blood glucose of diabetic mice after oral administration of 5mg/kg of V6-C10 prepared in example 3, wherein glucose tolerance test IPGTT was performed at 4, 7 and 10 hours after administration of V6-C10, respectively.
FIG. 7 is a graph showing the change in blood glucose of diabetic mice after oral administration of 5mg/kg of V6-C14 prepared in example 4, wherein glucose tolerance test IPGTT was performed at 4, 7 and 10 hours after administration of V6-C14, respectively.
FIG. 8 is a graph showing the change in blood glucose of diabetic mice after oral administration of 5mg/kg of V6-C18 prepared in example 5, wherein glucose tolerance test IPGTT was performed at 4, 7 and 10 hours after administration of V6-C18, respectively.
FIG. 9 is a graph showing the change in blood glucose of diabetic mice after oral administration of 5mg/kg of V6-pen prepared in example 6, wherein glucose tolerance test IPGTT was performed at 4, 7 and 10 hours after the administration of V6-pen, respectively.
FIG. 10 shows the blood glucose changes of diabetic mice after oral administration of 3mg/kg of the alkoxy polyvanadate derivatives V6-C10 and V6-C14 prepared in the examples, respectively, or injection of 1IU/kg of natural insulin or insulin derivative (insulin detemir), respectively.
FIG. 11 shows the change of hypoglycemic index of diabetic mice after oral administration of 3mg/kg of the alkoxy polyvanadate derivatives V6-C10 and V6-C14 prepared in the examples, respectively, or injection of 1IU/kg of natural insulin or insulin derivative (insulin detemir), respectively.
FIG. 12 is a graph showing the response of diabetic mice to IPGTT after oral administration of V6-C10 prepared in example 3 and V6-C14 prepared in example 4 (0.5 mg/kg, 1mg/kg, 2mg/kg, respectively).
FIG. 13 is a graph of STZ-induced changes in blood glucose in diabetic mice orally administered 3mg/kg V6-C14 prepared in example 4 and in healthy mice without any treatment, wherein the mice were subjected to the glucose tolerance test IPGTT at 3 hours after administration of V6-C14.
FIG. 14 is a graph of STZ-induced changes in blood glucose in diabetic mice injected with 3IU/kg of an insulin derivative (insulin detemir) and in healthy mice without any treatment, wherein the mice were subjected to the glucose tolerance test IPGTT at hour 3 after administration of V6-C14.
FIG. 15 is a graph showing the response rate of STZ-induced diabetic mice orally administered with 3mg/kg of V6-C14 prepared in example 4, STZ-induced diabetic mice injected with 3IU/kg of an insulin derivative (insulin detemir), and untreated healthy mice before the glucose tolerance test IPGTT.
FIG. 16 is a graph showing the response rates of STZ-induced diabetic mice orally administered with 3mg/kg of V6-C14 prepared in example 4, STZ-induced diabetic mice injected with 3IU/kg of an insulin derivative (insulin detemir), and healthy mice without any treatment in a glucose tolerance test IPGTT.
FIG. 17 shows the change of blood glucose in healthy mice in example 14 after oral administration of V6-14 and injection of native insulin and an insulin derivative (insulin detemir), respectively.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but the embodiments of the present invention are not limited thereto.
The experimental methods used in the following examples are all conventional methods unless otherwise specified; reagents, materials and the like used in the following examples are commercially available unless otherwise specified.
Method of use of continuous glucose monitor (Dexcom) in the following examples: the sensors of the glucose monitor were implanted subcutaneously in mice, and the mice were injected with native insulin or insulin derivatives (insulin detemir), or the polyvanadate alkoxy derivatives prepared in the examples were orally administered after calibration, according to the manufacturer's instructions.
The insulin derivative (insulin detemir) described in the following examples is named as noro and pencils, the product name is insulin detemir injection, and the manufacturer is danish norand nord company, national drug standard character J20140106.
Example 1
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol acetic anhydride, then 0.1g DMAP, 2mmol triethylamine and 20mL CH are added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. By exchange of H with cation exchange resins+Polyvanadate alkoxy derivatives as cations to obtain HV6O13{(OCH2)3CCH2OCOCH3}2]。
Example 2
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol of acetic anhydride, then 0.1g of DMAP, 2mmol of triethylamine and 20mL of CH are added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. By exchange of H with cation exchange resins+Polyvanadate alkoxy derivatives as cations, and exchange with Al by ion exchange3+Polyvanadate alkoxy derivatives as cations to give Al2[V6O13{(OCH2)3CCH2OCOCH3}2]3And is marked as V6-C2.
Example 3
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol decanoic anhydride, then 0.25g DMAP, 2mmol triethylamine and 20mL CH were added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCO(CH2)8CH3}2]And is marked as V6-C10.
Example 4
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol myristic anhydride, then 0.3g DMAP, 2mmol triethylamine and 20mL CH were added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCO(CH2)12CH3}2]And is marked as V6-C14.
Example 5
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol stearic anhydride, then 0.35g DMAP, 2mmol triethylamine and 20mL CH were added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCO(CH2)16CH3}2]And is marked as V6-C18.
Example 6
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol of benzoic anhydride, then 0.35g of DMAP, 2mmol of triethylamine and 20mL of CH are added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCOC6H5}2]And is marked as V6-phen.
Example 7
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol acetic acid, then 0.1g DMAP, 2mmol triethylamine and 20mL CH were added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. By passingCation exchange resin exchange with H+Polyvanadate alkoxy derivatives as cations to obtain HV6O13{(OCH2)3CCH2OCOCH3}2]。
Example 8
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol acetic acid, then 0.1g DMAP, 2mmol triethylamine and 20mL CH were added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. By exchange of H with cation exchange resins+Polyvanadate alkoxy derivatives as cations, and exchange with Al by ion exchange3+Polyvanadate alkoxy derivatives as cations to give Al2[V6O13{(OCH2)3CCH2OCOCH3}2]3。
Example 9
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol of decanoic acid, then 0.25g of DMAP, 2mmol of triethylamine and 20mL of CH were added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCO(CH2)8CH3}2]。
Example 10
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol myristic acid, then 0.3g DMAP, 2mmol Triethylamine and 20mLCH3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCO(CH2)12CH3}2]。
Example 11
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol of stearic acid, then 0.35g of DMAP, 2mmol of triethylamine and 20mL of CH are added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCO(CH2)16CH3}2]。
Example 12
And (3) synthesis of POV derivatives. 1mmol of hexavanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) And 2mmol of benzoic acid, then 0.35g of DMAP, 2mmol of triethylamine and 20mL of CH are added3CN, stirring and reacting for 48h at 80 ℃. After cooling to room temperature, the product mixture obtained from the reaction was poured into 50mL of deionized water, and the red precipitate was collected by filtration. Exchanging Na out by cation exchange resin+Polyvanadate alkoxy derivatives as cations to obtain Na [ V ]6O13{(OCH2)3CCH2OCOC6H5}2]。
Example 13
The long-acting insulin sensitizing effect of the poly-vanadate alkoxy derivatives prepared in examples 3-6 is specifically illustrated by taking the examples as examples.
The construction of the diabetes mouse model adopts male d/b mice purchased from Shanghai Jiesi laboratory animals GmbH and the age of the mice is 6-8 weeks. After one week of adaptation, d/b mice were fasted for 4 hours, and then injected intraperitoneally with 150mg of Streptozotocin (STZ) according to the weight of the mice as per 1kg of mice. Next, the mice were allowed to feed ad libitum while blood was taken from the mice peripheral tail vein daily and their blood glucose levels were monitored using a portable blood glucose meter until the fasting mice blood glucose levels were above 400 mg/dL. The control group was: age-matched healthy mice were fed ad libitum under the same conditions while blood was taken from the peripheral tail vein of healthy mice daily and their blood glucose levels were monitored using a portable blood glucose meter.
Glucose tolerance test. The experimental groups were: the polyvanadate alkoxy derivatives prepared in examples 3 to 6 were orally administered to the STZ-induced diabetic mice at a dose of 0.5, 1, 2, 3, 5mg/kg (i.e., 0.5, 1, 2, 3, 5mg/kg) respectively, and fasted overnight. The control group was: the STZ-induced diabetic mice were injected with 1, 3, 5IU/kg (i.e., 1, 3, 5 IU/kg) of native insulin or insulin derivative (insulin detemir) respectively and fasted overnight. And (3) respectively monitoring the blood sugar of vein puncture at the tail ends of the mice of the experimental group and the control group by using a portable glucometer every 6min so as to track the activity of insulin, wherein the test results are shown in figures 2-5 and 10-11. At the same time, the mice (i.e., experimental group and control group mice) which were orally administered with the poly-vanadate alkoxy derivative or injected with the natural insulin or insulin derivative were injected with 1g/kg (i.e., 1 g/kg) of an aqueous glucose solution having a concentration of 10mmol/L after 4h, 7h and 10h or after 3h, and immediately after the injection of the aqueous glucose solution, glucose tolerance IPGTT test was performed, and thereafter, blood glucose was continuously monitored every 6min and a curve of blood glucose concentration versus time was prepared, and the results are shown in FIGS. 6-9 and 13-16, and then insulin responsiveness was quantified by measuring the area under the curve (integration within a 3 hour window from the glucose injection point and after the challenge), and the results are shown in FIG. 12. The results show that the long-acting insulin sensitizer can keep the blood sugar stably within a certain range, and avoid the condition of overhigh or overlow blood sugar and the serious complications.
Example 14
To demonstrate the special potential of the polyvanadate alkoxy derivative (V6-14) prepared in example 4, normoglycemic healthy mice were subjected to a glucose tolerance test. The same amount of the polyoxyvanadic acid alkoxy derivative prepared in example 4 was orally administered to healthy mice as the diabetic mice described above, or insulin derivative (insulin detemir) was injected to healthy mice in the same amount as the diabetic mice described above, and then blood glucose of the mice was monitored. To quantify the rate of induction of hypoglycemia, the hypoglycemic index is calculated by dividing the difference between the initial blood glucose value and the lowest blood glucose value by the time to reach the lowest point. Continuous glucose monitoring was performed by using a continuous glucose monitor (Dexcom). As shown in FIG. 17, the use of polyvanadate alkoxy derivatives having insulin-sensitizing activity can prevent hypoglycemia symptoms such as dizziness, fatigue, etc.
From the figure, it can be known that the covalent modification of poly-vanadate and fatty acid can improve the insulin sensitizing activity and further regulate the blood sugar level, and the combined use effect of poly-vanadate alkoxy derivative and insulin is better than that of the single use of insulin.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims (7)

1. The application of poly vanadate alkoxy derivative with insulin sensitizing activity in the field of biomedicine is characterized in that the poly vanadate alkoxy derivative is applied to the preparation of a medicine for regulating insulin sensitizing activity, and the molecular formula of the poly vanadate alkoxy derivative is A2[V6O13{(OCH2)3CCH2OCOR}2]3、A2[V10O18{(OCH2)3CCH2OCOR}2]3、B2[V6O13{(OCH2)3CCH2OCOR}2]Or B2[V10O18{(OCH2)3CCH2OCOR}2]Wherein A is Al or Fe, B is tetrabutylammonium, Na or H, R is phenyl or alkyl containing 1-17 carbon atoms, A or B and [ V ]6O13{(OCH2)3CCH2OCOR}2]By ionic bond, A or B with [ V ]10O18{(OCH2)3CCH2OCOR}2]Is connected with an ionic bond.
2. The use of the polyvanadate alkoxy derivative having insulin sensitizing activity according to claim 1, wherein R is CH3、(CH2)4CH3、(CH2)8CH3、(CH2)12CH3、(CH2)16CH3And C6H5One kind of (1).
3. The use of the polyvanadate alkoxy derivative having insulin-sensitizing activity according to claim 1, wherein the polyvanadate alkoxy derivative having insulin-sensitizing activity is prepared by the following method:
mixing vanadate or vanadate with anhydride or fatty acid or benzoic acid uniformly, adding an esterification reaction catalyst and an organic solvent, reacting at 60-100 ℃ for 36-60 hours, cooling, purifying, and then carrying out cation exchange to obtain a poly-vanadate alkoxy derivative with insulin sensitizing activity;
the vanadic acid is hexa-vanadic acid ((Bu)4N)2[V6O13{(OCH2)3CCH2OH}2]) Or decavanadic acid (Bu)4N)2[V10O18{(OCH2)3CCH2OH}2]The vanadate is hexavanadate or decavanadate;
the molar ratio of the vanadate or vanadate to the anhydride or fatty acid or benzoic acid is 1: 2 to 3.
4. The use of the polyvanadate alkoxy derivative having insulin sensitizing activity according to claim 3, wherein said anhydride is at least one of acetic anhydride, hexanoic anhydride, decanoic anhydride, myristic anhydride, creatinine, stearic anhydride and benzoic anhydride;
the fatty acid is a fatty acid containing 1-18 carbon atoms; or at least one of acetic acid, caproic acid, capric acid, myristic acid and stearic acid;
the vanadate is at least one of bismuth vanadate, sodium vanadate, copper vanadate, ammonium vanadate, ferric vanadate, calcium vanadate, zinc vanadate and silver vanadate.
5. The application of the poly-vanadate alkoxy derivative with insulin sensitizing activity in the biomedical field according to claim 4, wherein the molar ratio of the esterification reaction catalyst to the acid anhydride or the fatty acid or the benzoic acid is (0.01-2): 1, or (0.4-1.4): 1.
6. the use of the polyvanadate alkoxy derivative having insulin sensitizing activity according to claim 4 or 5, wherein the concentration of the acid anhydride or the fatty acid or the benzoic acid in the organic solvent is 0.05 to 1 mol/L.
7. The application of the poly-vanadate alkoxy derivative with the insulin sensitizing activity in the biomedical field according to claim 6, wherein the esterification reaction catalyst is 4-dimethylaminopyridine or N, N' -dicyclohexylcarbodiimide; the organic solvent is at least one of triethylamine, acetonitrile, N' -dimethylformamide and dimethyl sulfoxide; the organic solvent is triethylamine and acetonitrile, and the weight ratio of triethylamine to acetonitrile is 1 mmol: the obtained mixed solvent was mixed in a proportion of 10 mL.
CN201911022214.8A 2019-10-25 2019-10-25 Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof Active CN112707816B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911022214.8A CN112707816B (en) 2019-10-25 2019-10-25 Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911022214.8A CN112707816B (en) 2019-10-25 2019-10-25 Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN112707816A CN112707816A (en) 2021-04-27
CN112707816B true CN112707816B (en) 2022-01-18

Family

ID=75541436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911022214.8A Active CN112707816B (en) 2019-10-25 2019-10-25 Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN112707816B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409781A (en) * 2018-04-28 2018-08-17 湖北工业大学 One kind six vanadic acid-l-Alanine tert-butyl ester derivative and the preparation method and application thereof
CN108558936A (en) * 2018-04-28 2018-09-21 湖北工业大学 One kind six vanadic acid-l-Alanine methyl ester derivation and the preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946151B2 (en) * 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409781A (en) * 2018-04-28 2018-08-17 湖北工业大学 One kind six vanadic acid-l-Alanine tert-butyl ester derivative and the preparation method and application thereof
CN108558936A (en) * 2018-04-28 2018-09-21 湖北工业大学 One kind six vanadic acid-l-Alanine methyl ester derivation and the preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Double-Tailed Fluorescent Surfactant with a Hexavanadate Cluster as the Head Group;Panchao Yin等;《Angewandte Chemie International Edition》;20111231;第50卷;第2521-2525页 *

Also Published As

Publication number Publication date
CN112707816A (en) 2021-04-27

Similar Documents

Publication Publication Date Title
KR920002131B1 (en) Process for preparing thiazolidinedione derivatives
DE1445154C3 (en) 1,4-Dihydro-1,8-naphthyridinderi derivatives and a process for their preparation
EP2181706A2 (en) Florfenicol esters for treating bacterial infections
CN112707816B (en) Polyvanadate alkoxy derivative with insulin sensitizing activity and preparation method and application thereof
DE2119964C3 (en) Methyl N (N5 methyl N1 nitroso carbamoyiyD glycosaminide and processes for its production
DE3217583A1 (en) 2-ARYL-TETRAAZAINDENE
CN103877593B (en) Based on the kidney targeting supermolecule and preparation method thereof of catechol beautify chitosan
CN1178946C (en) Vanadium compound and its preparing process and usage
CN106632455A (en) Vanadium complex with anti-diabetic effect as well as preparation method and application of vanadium complex
CN85101435A (en) Novel cpd N, N '-methylene-two (2 amino-5 sulfydryl-1,3,4 thiadiazoles) preparation method and contain the control vegetative bacteria of this compound, the disease sterilant
DE69213738T2 (en) THIAZOLIDINDIONE AS A HYPOGLYCAEMIC ACTIVE SUBSTANCE
CN107162913B (en) Novel deuterated phenylpropionic acid derivative, preparation method thereof and application thereof as medicine
CN103265607B (en) The preparation method of a kind of oleanolic acid derivate
CN108623625A (en) With active organic vanadium complex of para-insulin and preparation method thereof
CN115960020B (en) Caffeic acid nitrone compound and preparation method and application thereof
CN115282162B (en) Transdermal release nano-application for treating diabetes mellitus and preparation method thereof
CN107954938A (en) A kind of synthetic method of 1H- imidazoles -4- formic acid
CN114014852B (en) Fluorescent guide type super-oxygen enhanced photosensitizer dye based on benzophenoothiazine dimer, and preparation method and application thereof
US3928372A (en) 2-(3-Oxythiazolyl)benzimidazoles
CN105153050A (en) Quinocetone derivative and preparation method thereof
Batool et al. Conventional and Microwave-Assisted Synthesis of Fibric Acid based 1, 3, 4-Oxadiazol Derivatives and Evaluation of their in vivo Anti-hyperglycemic Activity
FR2686515A1 (en) Use of niobium derivatives as active principle of medicaments which are useful in the treatment and/or prevention of disorders of carbohydrate and/or lipid metabolism
EP2259785A2 (en) Fullerene therapies for inflammation
CN103599107B (en) Two (α-furnancarboxylic acid) vanadyl is as the novelty teabag of cancer therapy drug
Liu et al. Glucose‐lowering Activity of Amino Acid‐N‐phosphonic Acid Oxovanadium Complexes and Its Interaction with DNA

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant